Healthcare Industry News: atherosclerotic plaque
News Release - May 3, 2006
Medeikon Announces New VP of Intravascular Systems / MarketingTop Executive Named to Lead Medeikon's Intravascular Business
EWING, N.J.--(HSMN NewsFeed)--May 3, 2006--Medeikon Corporation, a leader in medical devices for physician diagnosis and treatment of cardiac and vascular disease, today announced that Willard W. (Bill) Hennemann, PhD., will join the company as Vice President of Vascular Systems / Marketing, effective April 3, 2006. This is the first position of this kind for Medeikon and will strengthen the company's continued commitment to advancing the clinical science and value of its products. In this new position, Dr. Hennemann will report to Fred Rappaport, President and Chief Executive Officer, and work closely with Operations in Catheter Probe Development. "Dr. Hennemann's leadership and expertise in interventional cardiology and the marketing and development of medical devices will be of immense value as we pursue new technologies in treating cardiac and vascular disease," said Rappaport. "With more than twenty years of exceptional operational and business achievement, Bill immediately brings a wealth of experience that will be critical to this important position," commented Rappaport, CEO.
As Vice President of Vascular Systems / Marketing, Bill will be instrumental in guiding product development, evaluating new and emerging technologies, and shaping the company's clinical research and business strategies. "The rapid evolution of technology for the diagnosis and treatment of cardiac and vascular disease makes interventional cardiology a very challenging and exciting field. Medeikon's technology provides solutions to several important clinical problems faced by interventional cardiologists on a daily basis. I look forward to joining the Medeikon team and contributing to the development and introduction of this exciting new technology," Bill stated.
Prior to joining Medeikon, Hennemann has held various positions of increasing responsibility at Cordis, Medtronic, Datascope and, most recently at CryoCath Technologies, where he was Vice President of R&D/ Interventional Vascular.
Dr. Hennemann holds a PhD in Zoology from the University of Florida, is an inventor on six medical device patents, and has authored over fifteen publications in the fields of biology and medicine.
Medeikon Corporation provides medical devices for physician diagnosis and treatment of cardiovascular disease. Medeikon's initial product, the XploraPD(TM) system, will enable accurate placement and full strut apposition during stent deployment, and allow the characterization of atherosclerotic plaque. The resolution of the system is sufficiently high to allow the detection and assessment of rupture-prone lesions, which are the primary cause of myocardial infarction and sudden cardiac death.
Medeikon is currently developing its technology and will license it to medical device manufacturers, pharmaceutical companies and other technology companies. Medeikon is a privately held company. Medeikon is currently engaged in a private placement for Round B financing, $15 million, through Janney Montgomery Scott LLC.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.